News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 109–144
- Matches
- 1143
- Sources here
- 22
- Companies here
- 14
Active search
1143 matching headlines
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Graphic Packaging Holding Company $GPK Shares Purchased by Cetera Investment Advisers
Cetera Investment Advisers significantly increased its stake in Graphic Packaging Holding Company (NYSE:GPK) by 207.5% in the first quarter, now holding 143,952 shares valued at $1.43 million. Despite substantial institutional ownership (99.67%), analyst sentiment remains cautious with a "Reduce" consensus rating and an average …
Lumexa outlines $235M-$241M 2026 adjusted EBITDA amid Hospital for Special Surgery joint venture expansion
Earnings Call Insights: Lumexa Imaging Holdings, Inc. (LMRI) Q2 2026 MANAGEMENT VIEW * CEO Caitlin Zulla said, "Q2 was a quarter of substantial progress as we continue to execute against the strategic priorities," and highlighted "driving strong same-center growth with an expanding mix of …
Packaging Corporation Of America (PKG) Set A Shipment Record, Does It Look Fairly Valued?
Packaging Corporation of America (PKG) recently reported Q2 results, matching revenue expectations but missing on EPS and guidance, while also setting a record for corrugated shipments. Despite mixed earnings, the stock has shown strong performance over the past year. Analysts project future earnings growth …
Agilon Health (AGL) Q2 2026 Earnings Call Transcript
Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Senior Vice President, Investor Relations - Evan Smith Chief Executive Officer - Timothy O'Rourke Chief Financial Officer - Jeffrey Schwaneke Full Conference Call Transcript Operator: Hello, everyone. Thank …
QT Imaging Holdings affirms $39.000M FY26 sales guidance
QT Imaging Holdings (NASDAQ: QTI) has reaffirmed its FY26 sales guidance at $39.000 million, which is consistent with prior reports but $0.200 million below the analyst consensus of $39.200 million. This stable guidance indicates a consistent operational outlook for the company, despite a slight …
Nano-X Imaging (NASDAQ: NNOX) Optimizes Nanox.AI Medical Imaging Framework for Intel Core Ultra Processors
Nano-X Imaging Ltd. (NASDAQ: NNOX) announced that its subsidiary Nanox.AI has optimized its medical imaging AI application framework for Intel Core Ultra processors using the Intel OpenVINO toolkit. This optimization enables healthcare facilities to deploy CT imaging AI applications on on-premise edge devices, keeping …
Lumexa Imaging Holdings Reports Q2 2026 Financial Results in SEC 8-K Filing
Lumexa Imaging Holdings, Inc. filed an 8-K report with the SEC on August 12, 2026, announcing its financial results for the quarter ended June 30, 2026. The report includes a press release (Exhibit 99.1) detailing the results of operations and financial condition, as well …
Earnings call transcript: QT Imaging misses Q2 2026 profit forecast
QT Imaging (QTI) reported strong Q2 2026 financial results, with revenue increasing by 103% year-over-year to $7.4 million, driven by higher scanner shipments. The company affirmed its 2026 revenue guidance of approximately $39 million, more than double the 2025 revenue, and is expanding its …
Lumexa: Q2 Earnings Snapshot
Lumexa Imaging Holdings Inc. (LMRI) reported Q2 earnings of $2.7 million, or 3 cents per share. Adjusted earnings were 20 cents per share, and revenue reached $264.2 million, exceeding analyst forecasts. The company projects full-year earnings between 71 cents and 77 cents per share, …
QT Imaging (QTI) Q2 2026 Earnings Call Transcript
QT Imaging (QTI) reported strong Q2 2026 financial results, with revenue increasing by 103% year-over-year to $7.4 million, driven by higher scanner shipments. The company affirmed its 2026 revenue guidance of approximately $39 million, more than double the 2025 revenue, and is expanding its …
Earnings Flash (LMRI) Lumexa Imaging Holdings, Inc. Reports Q2 Revenue $264.2M, vs. FactSet Est of $263.1M
Lumexa Imaging Holdings, Inc. (LMRI) announced its Q2 revenue of $264.2 million, surpassing FactSet's estimate of $263.1 million. The company also reiterated its full-year 2026 revenue guidance, projecting a range of $1.045 billion to $1.097 billion against an estimate of $1.066 billion. Lumexa Imaging …
Lumexa Imaging Announces Second Quarter 2026 Results
Lumexa Imaging (Nasdaq: LMRI) reported strong second-quarter 2026 results, showing a 5.1% increase in consolidated revenues to $264.2 million and a net income of $2.7 million. The company also updated its full-year 2026 outlook, reiterating revenue guidance and narrowing its Adjusted EBITDA range, reflecting …
QT Imaging Holdings (QTI) doubles Q2 revenue but books $11.1M net loss
QT Imaging Holdings reported a 103% increase in Q2 revenue to $7.4 million, driven by increased shipments of Breast Acoustic CT scanners. Despite this growth and reaffirmed 2026 revenue guidance of $39 million, the company posted an $11.1 million net loss, largely due to …
Footprint Reshuffle and Steady Dividend Could Be A Game Changer For Graphic Packaging Holding (GPK)
Graphic Packaging Holding Company (GPK) reported weaker Q2 2026 earnings but maintained its dividend and reaffirmed full-year sales guidance. The company is optimizing its footprint by divesting and closing facilities to improve cost efficiency. This strategic move aims to consolidate production capacity and stabilize …
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Agios Pharmaceuticals, Inc. (AGIO) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Agios Pharmaceuticals, Inc. (AGIO) following a significant stock drop. The investigation stems from Agios's announcement that its Phase 2 trial for tebapivat in sickle cell disease did not meet the necessary differentiation for continued …
Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3
Agilent Technologies Inc. announced that the FDA has approved the expanded use of its PD-L1 IHC 22C3 pharmDx for Dako Omnis platform. This approval allows for identifying patients with esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric or gastroesophageal junction adenocarcinoma …
Agilent Technologies, Inc. Stock 12‑Month Price Target Raised to $160.17, Implies 7% Upside
The average 12-month price target for Agilent Technologies, Inc. (A) stock has been raised from $159.33 to $160.17 by 18 analysts, with forecasts ranging from $135 to $185 per share. This new target implies a potential upside of approximately 7% from the August 11 …
Q4 2025 Agios Pharmaceuticals Inc Earnings Call Transcript
Agios Pharmaceuticals reported strong Q4 and full-year 2025 results, driven by the successful launch of AQVESME for thalassemia and robust PYRUKYND revenue. The company ended 2025 with $1.2 billion in cash, has a clear path to profitability, and is advancing its pipeline, including a …